Pharvaris N.V. (NASDAQ:PHVS) Stock Has Average Target Price of $59.53

Key Points

• Analyst sentiment is broadly positive: Pharvaris has a “Moderate Buy” consensus from 15 analysts, with 14 buy ratings and one sell rating. The average 12-month price target is $59.53, well above the reported share price of $31.41.
• The stock remains loss-making: Pharvaris reported quarterly EPS of -$0.81, missing the -$0.75 consensus estimate, and analysts expect a full-year loss of approximately $3.12 per share.
• Insiders have been selling shares: Company insiders sold 513,102 shares worth about $18.6 million over the past 90 days, while several institutional investors—including Wellington Management and Alyeska Investment Group—expanded their positions.

Shares of Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen analysts that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $59.53.

Several equities analysts recently weighed in on the company. Wells Fargo & Company boosted their price objective on Pharvaris from $55.00 to $65.00 and gave the stock an "overweight" rating in a research report on Wednesday, September 9th. Royal Bank Of Canada raised their target price on Pharvaris from $52.00 to $62.00 and gave the company an "outperform" rating in a report on Wednesday, September 9th. New Street Research set a $60.00 target price on Pharvaris in a report on Friday, August 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Pharvaris in a research report on Thursday, October 15th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th.

Pharvaris Trading Up 2.4%

NASDAQ PHVS opened at $31.41 on Friday. Pharvaris has a 1 year low of $21.02 and a 1 year high of $43.25. The company has a fifty day simple moving average of $33.98 and a 200 day simple moving average of $32.52. The company has a market cap of $2.05 billion, a P/E ratio of -10.30 and a beta of -2.46.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities research analysts forecast that Pharvaris will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling

In related news, President Peng Lu sold 100,000 shares of the company's stock in a transaction on Thursday, September 17th. The stock was sold at an average price of $35.00, for a total value of $3,500,000.00. Following the completion of the transaction, the president directly owned 64,953 shares in the company, valued at approximately $2,273,355. This represents a 60.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Elisabeth Bjork sold 52,500 shares of the firm's stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $37.89, for a total transaction of $1,989,225.00. Following the transaction, the director directly owned 15,167 shares of the company's stock, valued at $574,677.63. The trade was a 77.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 513,102 shares of company stock valued at $18,643,666 in the last ninety days. Company insiders own 11.84% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP acquired a new position in Pharvaris in the second quarter valued at about $1,143,000. Amundi increased its position in Pharvaris by 61.4% in the 2nd quarter. Amundi now owns 49,944 shares of the company's stock valued at $1,727,000 after acquiring an additional 18,992 shares in the last quarter. Moore Capital Management LP bought a new position in shares of Pharvaris in the second quarter worth about $1,522,000. Alyeska Investment Group L.P. raised its stake in shares of Pharvaris by 225.5% in the second quarter. Alyeska Investment Group L.P. now owns 406,829 shares of the company's stock worth $14,068,000 after acquiring an additional 281,829 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Pharvaris by 12.9% during the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after purchasing an additional 274,034 shares in the last quarter.

Pharvaris Company Profile

Pharvaris N.V. NASDAQ: PHVS is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of swelling. The company was founded in 2015 by individuals with experience in HAE drug development and aims to provide convenient, non-injectable treatment options for patients.

Pharvaris' lead investigational product is deucrictibant, an oral bradykinin B2 receptor antagonist designed for use both as an on-demand treatment for HAE attacks and as a preventive therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.